Register to get unlimited access to our investor forum and all editorial content, including our e-zine and weekly email. Registration is free and only takes a minute.
Showing fund managers & funds available in Investment Trust Insider. View fund & fund manager rankings globally

Funds & Fund Managers

All calculations in GBP, unless stated
over :
 Average Manager Total Return : -3.6% (31 October 2017 - 31 October 2018)
Total Return
1 of 106

7.0%

1 of 106

7.0%

3 of 106

6.0%

4 of 106

5.4%

4 of 106

5.4%

6 of 106

4.5%

7 of 106

4.4%

8 of 106

4.3%

8 of 106

4.3%

10 of 106

3.5%

10 of 106

3.5%

12 of 106

1.7%

13 of 106

1.1%

14 of 106

0.7%

14 of 106

0.7%

16 of 106

0.0%

17 of 106

-0.5%

18 of 106

-0.8%

19 of 106

-0.8%

20 of 106

-1.4%

21 of 106

-1.7%

22 of 106

-1.9%

23 of 106

-2.0%

24 of 106

-2.2%

25 of 106

-2.4%

26 of 106

-2.4%

27 of 106

-2.4%

27 of 106

-2.4%

29 of 106

-2.5%

29 of 106

-2.5%

29 of 106

-2.5%

32 of 106

-2.5%

33 of 106

-2.6%

34 of 106

-2.8%

35 of 106

-2.9%

36 of 106

-3.0%

36 of 106

-3.0%

38 of 106

-3.1%

38 of 106

-3.1%

38 of 106

-3.1%

41 of 106

-3.3%

42 of 106

-3.3%

42 of 106

-3.3%

44 of 106

-3.3%

44 of 106

-3.3%

46 of 106

-3.4%

47 of 106

-3.4%

47 of 106

-3.4%

47 of 106

-3.4%

50 of 106

-3.4%

51 of 106

-3.5%

52 of 106

-3.6%

53 of 106

-3.6%

53 of 106

-3.6%

55 of 106

-3.6%

55 of 106

-3.6%

57 of 106

-3.8%

57 of 106

-3.8%

59 of 106

-3.8%

59 of 106

-3.8%

61 of 106

-3.9%

62 of 106

-3.9%

63 of 106

-4.0%

64 of 106

-4.1%

65 of 106

-4.4%

66 of 106

-4.4%

66 of 106

-4.4%

68 of 106

-4.5%

68 of 106

-4.5%

68 of 106

-4.5%

71 of 106

-4.6%

71 of 106

-4.6%

73 of 106

-4.6%

74 of 106

-4.7%

74 of 106

-4.7%

76 of 106

-4.7%

77 of 106

-5.0%

78 of 106

-5.1%

79 of 106

-5.4%

80 of 106

-5.4%

81 of 106

-5.5%

81 of 106

-5.5%

83 of 106

-5.6%

84 of 106

-5.8%

85 of 106

-5.8%

86 of 106

-5.9%

86 of 106

-5.9%

88 of 106

-6.0%

89 of 106

-6.2%

90 of 106

-6.5%

91 of 106

-7.3%

91 of 106

-7.3%

93 of 106

-7.5%

94 of 106

-8.3%

95 of 106

-8.6%

96 of 106

-8.6%

96 of 106

-8.6%

98 of 106

-8.7%

99 of 106

-8.8%

100 of 106

-9.1%

101 of 106

-9.2%

102 of 106

-10.0%

102 of 106

-10.0%

104 of 106

-10.4%

105 of 106

-12.5%

106 of 106

-16.1%

Managers with less than 12 months history are below. View 1 month performance
Show more managers
Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated). Portions of the information contained on this page was derived by Citywire Financial Publishers Ltd using content supplied by Lipper, A Reuters Company.

Perpetual Income backs Mark Barnett but fears 11% discount

Board of Perpetual Income & Growth states unease at ten-year under-performance of its share price but backs Mark Barnett to turn round UK equity income trust saying all fund managers suffer ‘ups and downs’.

Securities Trust turns to ‘Tough Mudder’ to exit discount hole

Securities Trust of Scotland hires digital marketing expert to its board as the 3.8% yielding global income trust strives to avoid falling foul of its tough discount control policy.

Hipgnosis, a true ‘Belieber’, buys Poo Bear song catalogue

High-yielding music royalty investment company trust has bought the catalogue of songwriter Jason Boyd - aka Poo Bear - behind some of Justin Bieber’s biggest hits.

Brexit fears hit pound as tobacco goes up in smoke

Tobacco stocks fall to bottom of FTSE 100 on reports of US menthol cigarette ban while fears over Brexit deal hit pound.

Trust in Focus: Invesco Perpetual UK Smaller buys slice of Woodford’s AJ Bell

A review of the revived and high-yielding Invesco Perpetual UK Smaller Companies trust which has bought £1.7 million of Neil Woodford’s legacy stake in funds supermarket AJ Bell.

Hedge fund shorts Woodford Patient Capital Trust shares

After dealing with short-selling attacks on his key holdings, Neil Woodford now has a hedge fund shorting shares in his trust.

Investors pour £235m into 6%-yielding BioPharma Credit

BioPharma Credit is poised to smash through the £1 billion mark after raising $305 million (£235 million), more than double its original target, in an oversubscribed share placing.

Chelverton gets its first VCT bailing out Oxford Technology

Oxford Technology 2 VCT turns to smaller company boutique Chelverton Asset Management in bid to extend life of tiny venture capital trust and avoid costly tax bill for shareholders.

Biopharma Credit raising $150m to inject in drug loans

High-yielding life sciences debt fund hopes to issue £115 million of shares having invested twice as much in a C-share issue earlier this year.

Amgen boosts Patient Capital’s case but not its share price

A recent run of good news for Woodford Patient Capital Trust continues with Oxford Nanopore, its third biggest holding, receiving a £50 million investment from US biotech giant Amgen.